A
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Dr. Abdul H. Khan's research focuses on preclinical drug development, with a specialization in integrative physiology, pharmacology, and in vivo translational research. His work specifically targets cardiovascular, renal, and anti-fibrotic drug development.
His investigations have included examining the effects of specific molecules on kidney function and toxicity, such as the kidney-targeted epoxyeicosatrienoic acid analog, EET-F01, which has been studied for its potential to reduce inflammation and oxidative stress in cisplatin-induced nephrotoxicity. Dr. Khan has also explored multitarget molecules, like PTUPB, for treating diabetic nephropathy in rats, and investigated the role of chloride channel 6 (CLC-6) in vascular smooth muscle contractility and arterial stiffness. His recent work also extends to the impact of microplastics on reproductive toxicity in male mice and the sex-based differences in kidney injury following unilateral ureteral obstruction in mice. Furthermore, his research has delved into dual-acting molecules that combine soluble epoxide hydrolase inhibition with farnesoid X receptor agonism to attenuate renal inflammation and fibrosis.
With over 15 years of experience, Dr. Khan has authored or co-authored 194 peer-reviewed articles and has an H-index of 31. He has also contributed to 2 book chapters and over 50 scientific abstracts. His expertise has been recognized with multiple awards and grants. Dr. Khan leads a research group and has a history of mentoring students and postdoctoral fellows.
Metrics
- h-index: 31
- Publications: 194
- Citations: 3,186
Selected Publications
-
Renal hemodynamics underlie hepatorenal physiology in bile duct-ligated rats (2026)
-
Renoprotective approaches against anthracycline nephrotoxicity (2026)
-
EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage (2025)
-
Dual acting inhibitor of soluble epoxide hydrolase and Cyclooxygenase-2, attenuates glomerular injury in renal hypoplasia mice (2025)
-
Transforming growth factor β receptor 1 and mitogen-activated protein 4 kinase 4 dual inhibitor, TK-850, reduces renal fibrosis in unilateral ureteral–obstructed mice (2025)
-
591 Low kidney mass contributes to enhanced fractionated irradiation-induced renal hemodynamic dysfunction in mice (2025)
-
Editorial: Debates in experimental pharmacology and drug discovery 2023: innovative approaches to chronic kidney disease drug discovery, identification of targets and safety assessment (2025)
Collaboration Network
Top Collaborators
John D. Imig
University of Arkansas for Medical Sciences
9 shared publications
In database
- Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity
- Loss of Chloride Channel 6 (CLC-6) Affects Vascular Smooth Muscle Contractility and Arterial Stiffness via Alterations to Golgi Calcium Stores
- Salt-sensitive hypertension after reversal of unilateral ureteral obstruction
- Kidney Injury by Unilateral Ureteral Obstruction in Mice Lacks Sex Differences
- Dual soluble epoxide hydrolase inhibitor – farnesoid X receptor agonist interventional treatment attenuates renal inflammation and fibrosis
Showing 5 of 9 shared publications
Samaneh Goorani
University of Arkansas for Medical Sciences
8 shared publications
In database
- Polystyrene microplastics cause reproductive toxicity in male mice
- Salt-sensitive hypertension after reversal of unilateral ureteral obstruction
- Kidney Injury by Unilateral Ureteral Obstruction in Mice Lacks Sex Differences
- Editorial: Debates in experimental pharmacology and drug discovery 2023: innovative approaches to chronic kidney disease drug discovery, identification of targets and safety assessment
- 591 Low kidney mass contributes to enhanced fractionated irradiation-induced renal hemodynamic dysfunction in mice
Showing 5 of 8 shared publications
Mandana Kamgar
Medical College of Wisconsin (US)
5 shared publications
- Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology
- Association of total neoadjuvant therapy with favorable clinical outcomes in patients with locally advanced esophageal and gastroesophageal junction adenocarcinomas (LA-GEJ CA).
- Abstract PO-055: Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer
- Impact of<i> KRAS</i> alterations in localized pancreatic cancer (PC).
- Examination for the Presence of an Oligo-Metastatic State in Patients with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma Undergoing Systemic Chemotherapy
Kulwinder S. Dua
Medical College of Wisconsin (US)
4 shared publications
- Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology
- Association of total neoadjuvant therapy with favorable clinical outcomes in patients with locally advanced esophageal and gastroesophageal junction adenocarcinomas (LA-GEJ CA).
- Impact of<i> KRAS</i> alterations in localized pancreatic cancer (PC).
- Examination for the Presence of an Oligo-Metastatic State in Patients with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma Undergoing Systemic Chemotherapy
William A. Hall
Medical College of Wisconsin (US)
4 shared publications
- Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology
- Abstract PO-055: Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer
- Impact of<i> KRAS</i> alterations in localized pancreatic cancer (PC).
- Examination for the Presence of an Oligo-Metastatic State in Patients with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma Undergoing Systemic Chemotherapy
Douglas B. Evans
Medical College of Wisconsin (US)
4 shared publications
- Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology
- Abstract PO-055: Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer
- Impact of<i> KRAS</i> alterations in localized pancreatic cancer (PC).
- Examination for the Presence of an Oligo-Metastatic State in Patients with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma Undergoing Systemic Chemotherapy
Susan Tsai
Medical College of Wisconsin (US)
4 shared publications
- Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology
- Abstract PO-055: Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer
- Impact of<i> KRAS</i> alterations in localized pancreatic cancer (PC).
- Examination for the Presence of an Oligo-Metastatic State in Patients with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma Undergoing Systemic Chemotherapy
Ben George
Medical College of Wisconsin (US)
4 shared publications
- Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology
- Association of total neoadjuvant therapy with favorable clinical outcomes in patients with locally advanced esophageal and gastroesophageal junction adenocarcinomas (LA-GEJ CA).
- Impact of<i> KRAS</i> alterations in localized pancreatic cancer (PC).
- Examination for the Presence of an Oligo-Metastatic State in Patients with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma Undergoing Systemic Chemotherapy
Abhishek Mishra
University of Arkansas for Medical Sciences
4 shared publications
In database
- Kidney Injury by Unilateral Ureteral Obstruction in Mice Lacks Sex Differences
- 591 Low kidney mass contributes to enhanced fractionated irradiation-induced renal hemodynamic dysfunction in mice
- Transforming growth factor β receptor 1 and mitogen-activated protein 4 kinase 4 dual inhibitor, TK-850, reduces renal fibrosis in unilateral ureteral–obstructed mice
- EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage
Aditya Shreenivas
Medical College of Wisconsin (US)
3 shared publications
- Association of total neoadjuvant therapy with favorable clinical outcomes in patients with locally advanced esophageal and gastroesophageal junction adenocarcinomas (LA-GEJ CA).
- Impact of<i> KRAS</i> alterations in localized pancreatic cancer (PC).
- Examination for the Presence of an Oligo-Metastatic State in Patients with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma Undergoing Systemic Chemotherapy
Sakti Chakrabarti
Medical College of Wisconsin (US)
3 shared publications
- Association of total neoadjuvant therapy with favorable clinical outcomes in patients with locally advanced esophageal and gastroesophageal junction adenocarcinomas (LA-GEJ CA).
- Impact of<i> KRAS</i> alterations in localized pancreatic cancer (PC).
- Examination for the Presence of an Oligo-Metastatic State in Patients with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma Undergoing Systemic Chemotherapy
Bradley A. Erickson
Froedtert Hospital (US)
3 shared publications
- Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology
- Impact of<i> KRAS</i> alterations in localized pancreatic cancer (PC).
- Examination for the Presence of an Oligo-Metastatic State in Patients with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma Undergoing Systemic Chemotherapy
Kathleen K. Christians
Medical College of Wisconsin (US)
3 shared publications
- Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology
- Impact of<i> KRAS</i> alterations in localized pancreatic cancer (PC).
- Examination for the Presence of an Oligo-Metastatic State in Patients with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma Undergoing Systemic Chemotherapy
Ashraf El‐Meanawy
Medical College of Wisconsin (US)
3 shared publications
- Salt-sensitive hypertension after reversal of unilateral ureteral obstruction
- Kidney Injury by Unilateral Ureteral Obstruction in Mice Lacks Sex Differences
- Dual acting inhibitor of soluble epoxide hydrolase and Cyclooxygenase-2, attenuates glomerular injury in renal hypoplasia mice
Srivats Madhavan
Medical College of Wisconsin (US)
2 shared publications
- Association of total neoadjuvant therapy with favorable clinical outcomes in patients with locally advanced esophageal and gastroesophageal junction adenocarcinomas (LA-GEJ CA).
- Impact of<i> KRAS</i> alterations in localized pancreatic cancer (PC).
Similar Researchers
Based on overlapping research topics
J.C. Hsu
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Pharmacological Effects and Toxicity Studies
Drug-Induced Hepatotoxicity and Protection
JT Painter
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
John Imig
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
RANEY L. HALEY
National Center for Toxicological Research
Cardiovascular Function and Risk Factors
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Jade N. Hess
National Center for Toxicological Research
Pharmacological Effects and Toxicity Studies
Drug-Induced Hepatotoxicity and Protection
Metabolism and Genetic Disorders
Marjan Boerma
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Pharmacological Effects and Toxicity Studies
Cancer Treatment and Pharmacology